125 related articles for article (PubMed ID: 18241737)
1. Review and update of the use of urokinase in the prevention and management of CVAD-related complications in pediatric oncology patients.
Simon A; Bode U; Lieber K; Beutel K; Fleischhack G
Am J Infect Control; 2008 Feb; 36(1):54-8. PubMed ID: 18241737
[TBL] [Abstract][Full Text] [Related]
2. [Diagnostics and management of central venous line infections in pediatric cancer patients].
Beutel K; Simon A
Klin Padiatr; 2005 Nov; 217 Suppl 1():S91-100. PubMed ID: 16288355
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and treatment of catheter-related infections in paediatric oncology: an update.
Simon A; Bode U; Beutel K
Clin Microbiol Infect; 2006 Jul; 12(7):606-20. PubMed ID: 16774556
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic urokinase in the management of long-term venous access devices in children: a Children's Oncology Group study.
Dillon PW; Jones GR; Bagnall-Reeb HA; Buckley JD; Wiener ES; Haase GM;
J Clin Oncol; 2004 Jul; 22(13):2718-23. PubMed ID: 15226339
[TBL] [Abstract][Full Text] [Related]
5. Continuous infusion of low-dose urokinase in the treatment of central venous catheter thrombosis in infants and children.
Bagnall HA; Gomperts E; Atkinson JB
Pediatrics; 1989 Jun; 83(6):963-6. PubMed ID: 2657625
[TBL] [Abstract][Full Text] [Related]
6. Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies.
van Rooden CJ; Schippers EF; Guiot HF; Barge RM; Hovens MM; van der Meer FJ; Rosendaal FR; Huisman MV
J Clin Oncol; 2008 Jan; 26(3):428-33. PubMed ID: 18202420
[TBL] [Abstract][Full Text] [Related]
7. Consensus recommendations for use of central venous access devices in haemophilia.
Ewenstein BM; Valentino LA; Journeycake JM; Tarantino MD; Shapiro AD; Blanchette VS; Hoots WK; Buchanan GR; Manco-Johnson MJ; Rivard GE; Miller KL; Geraghty S; Maahs JA; Stuart R; Dunham T; Navickis RJ
Haemophilia; 2004 Sep; 10(5):629-48. PubMed ID: 15357790
[TBL] [Abstract][Full Text] [Related]
8. Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia.
Jeng MR; O'Brien M; Wong W; Zoland J; Lea J; Tang N; Glader B
Haemophilia; 2009 Nov; 15(6):1272-80. PubMed ID: 19601989
[TBL] [Abstract][Full Text] [Related]
9. Urokinase administration in pediatric patients with occluded central venous catheters.
Wachs T
J Intraven Nurs; 1990; 13(2):100-2. PubMed ID: 2313458
[TBL] [Abstract][Full Text] [Related]
10. Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial.
Haire WD; Deitcher SR; Mullane KM; Jaff MR; Firszt CM; Schulz GA; Schuerr DM; Schwartz LB; Mouginis TL; Barton RP
Thromb Haemost; 2004 Sep; 92(3):575-82. PubMed ID: 15351854
[TBL] [Abstract][Full Text] [Related]
11. Restoring patency to central venous access devices.
Cummings-Winfield C; Mushani-Kanji T
Clin J Oncol Nurs; 2008 Dec; 12(6):925-34. PubMed ID: 19064386
[TBL] [Abstract][Full Text] [Related]
12. Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders.
Komvilaisak P; Connolly B; Naqvi A; Blanchette V
Haemophilia; 2006 Dec; 12 Suppl 6():87-93. PubMed ID: 17123400
[TBL] [Abstract][Full Text] [Related]
13. Developing a protocol to prevent and treat pediatric central venous catheter occlusions.
Harris JL; Maguire D
J Intraven Nurs; 1999; 22(4):194-8. PubMed ID: 10476135
[TBL] [Abstract][Full Text] [Related]
14. Central venous access devices for paediatric patients with haemophilia: a single-institution experience.
Titapiwatanakun R; Moir C; Pruthi RK; Stavlo PL; Schmidt KA; Rodriguez V
Haemophilia; 2009 Jan; 15(1):168-74. PubMed ID: 19149849
[TBL] [Abstract][Full Text] [Related]
15. Dose-ranging trial with a recombinant urokinase (urokinase alfa) for occluded central venous catheters in oncology patients.
Deitcher SR; Fraschini G; Himmelfarb J; Schuman E; Smith TJ; Schulz GA; Firszt CM; Mouginis TL
J Vasc Interv Radiol; 2004 Jun; 15(6):575-80. PubMed ID: 15178717
[TBL] [Abstract][Full Text] [Related]
16. Removal of embedded central venous catheters.
Lesher AP; Kratz JM; Smith CD
J Pediatr Surg; 2008 Jun; 43(6):1030-4. PubMed ID: 18558178
[TBL] [Abstract][Full Text] [Related]
17. Are urokinase rinses needed to reduce catheter-related bloodstream infections when standard preventive guidelines are observed?
Blot F; Gachot B; Nitenberg G
J Clin Oncol; 2008 May; 26(14):2415-6; author reply 2416. PubMed ID: 18467738
[No Abstract] [Full Text] [Related]
18. Implantable port devices are catheters of choice for administration of chemotherapy in pediatric oncology patients-a clinical experience in Pakistan.
Hooda B; Lalani G; Fadoo Z; Billoo G
Ann N Y Acad Sci; 2008 Sep; 1138():43-6. PubMed ID: 18837881
[TBL] [Abstract][Full Text] [Related]
19. Recombinant tissue plasminogen activator for central venous access device occlusion.
Hooke C
J Pediatr Oncol Nurs; 2000 Jul; 17(3):174-8. PubMed ID: 10944865
[TBL] [Abstract][Full Text] [Related]
20. Surveillance methods for central venous access device-associated infections in Canadian pediatric hospitals.
Langley JM; LaRoche L; Hanakowski M
Can J Infect Control; 1995; 10(3):80-2. PubMed ID: 8555515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
